Evidence map›Paper›PMID 42377737›Full record

ArticleAdvances in therapy2026

Real-World Adult Height Outcomes in Girls with Central Precocious Puberty Receiving GnRHa Monotherapy or Combined with Growth Hormone: A Cohort Study in China.

Fei Wang, Yan Li, Yu Yang, Wei Gu, Xuan Xu, Haiying Wu, Guimei Li, Xiaoqin Yin, Shasha Zhou, Pin Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fei Wang *Department of Endocrinology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200040, China.
Yan Li *Department of Endocrinology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200040, China.
Yu YangDepartment of Endocrinology, Genetics and Metabolism, Jiangxi Provincial Children's Hospital, Nanchang, 330006, China.
Wei GuDepartment of Endocrinology, Genetics and Metabolism, Children's Hospital of Nanjing Medical University, Nanjing, 210008, China.
Xuan XuDepartment of Pediatric Endocrinology, Hunan Provincial People's Hospital, Changsha, 410002, China.
Haiying WuDepartment of Endocrinology, Genetics and Metabolism, Children's Hospital of Soochow University, Suzhou, 215000, China.
Guimei LiDepartment of Pediatrics, Shandong Provincial Hospital, Jinan, 250021, China.
Xiaoqin YinDepartment of Endocrinology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200040, China.
Shasha ZhouDepartment of Endocrinology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200040, China.
Pin LiDepartment of Endocrinology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200040, China. lip@shchildren.com.cn.ORCID http://orcid.org/0000-0002-6144-0750

Funding

China University-Industry-Research Innovation Fund 2024DR016National Natural Science Foundation of China 82201797School of Medicine, Shanghai Jiao Tong University GSGH-2023-001Shanghai Clinical Research Data Sharing and Simulated RCT Project SHDC2024CRI068Shanghai Jiao Tong University School of Medicine Education Development Foundation, Science and Technology Commission of Shanghai Municipality 24Y12800700
6 · The paper itself

Abstract

introductionAlthough gonadotropin-releasing hormone analogs (GnRHa) are the standard treatment for central precocious puberty (CPP), the efficacy of GnRHa monotherapy in older children (around 8 years) and that of combination therapy with recombinant human growth hormone (rhGH) both remain unclear. This study aims to evaluate the real-world efficacy of each regimen.

methodsThis retrospective cohort study enrolled Chinese girls with CPP. Two groups were formed: GnRHa monotherapy and GnRHa + rhGH combination therapy. Outcomes included adult height gain [AHG, final adult height (FAH) standard deviation score (SDS)- predicted adult height (PAH) SDS]，genetic height gain [GHG, FAH SDS-target height (Tht) SDS], and change in height (FAH SDS - baseline height SDS).

resultsIn the GnRHa group, the mean age at treatment initiation was 8.87 ± 0.87 years. After 17.87 months of treatment, the AHG was 1.33 SDS (0.82, 2.00). In the GnRHa + rhGH group, the mean age at treatment initiation was 9.01 ± 0.80 years. After 23.02 months of GnRHa treatment and 14.02 months of rhGH treatment, the group showed significantly greater AHG [1.72 SDS (1.24, 2.59)].

conclusionsGnRHa monotherapy initiated after age 8 may still provide meaningful height gains, and adding rhGH is associated with improved FAH in patients with severe baseline height impairment.

Indexed as

Body HeightGonadotropin-Releasing HormoneHuman Growth HormonePuberty, PrecociousChildChinaCohort StudiesDrug Therapy, CombinationFemaleHumansPuberty InhibitorsPuberty SuppressionRecombinant ProteinsRetrospective StudiesTreatment OutcomeGonadotropin-Releasing HormoneHuman Growth HormonePuberty InhibitorsRecombinant ProteinsAdult height gainCentral precocious pubertyGonadotropin-releasing hormone analogsRecombinant human growth hormone

Identifiers

PMID42377737
PMCPMC13499718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.